Jessica K. Altman

Hematology | Oncology
675 N St Clair St Ste 21-100
Galter Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 164 publications

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

Journal: Future oncology (London, England)
Published: July 11, 2026

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: June 15, 2026

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study.

Journal: Haematologica
Published: April 23, 2026

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia.

Journal: Blood
Published: March 18, 2026

A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib.

A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib.

Journal: Echocardiography (Mount Kisco, N.Y.)
Published: March 11, 2026

Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study.

Cardiovascular Events in Patients With Acute Myeloid Leukemia Treated With Venetoclax: A Multicenter Cohort Study.

Journal: JACC. Advances
Published: January 22, 2026

Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.

Donor-derived acute myeloid leukemia after solid organ transplant: evidence for leukemic stem cell transmission.

Journal: Leukemia & lymphoma
Published: December 23, 2025

Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?

Targeted triplet therapies incorporating FLT3 or IDH inhibitors: ready for prime time?

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Journal: Blood
Published: November 17, 2025

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

Journal: Blood advances
Published: October 27, 2025

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Survival after intensive therapy or clofarabine in fit older adults with acute myeloid leukemia: E2906 phase 3 trial.

Journal: Blood neoplasia
Published: October 06, 2025

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.

Journal: Blood cancer journal
Published: October 05, 2025
Showing 1-12 of 164

Last Updated: 09/26/2026